Last updated: about 1 month ago
AstraZeneca's Imfinzi Breaks Ground with EU Approval for Limited-Stage Small Cell Lung Cancer
AstraZeneca's Imfinzi receives EU approval as the first immunotherapy for LS-SCLC, showing significant survival benefits. This landmark decision highlights advancements in cancer care.